Emzor Pharmaceutical Industries Limited has secured N26.7 billion through a domestic bond issuance to finance the expansion of its manufacturing operations and complete a major anti-malarial Active Pharmaceutical Ingredient (API) production plant.
The Series 1 Fixed Rate Bond, valued at $19.8 million, was issued by Emzor Pharma Funding SPV Plc and listed on the FMDQ Group Exchange.
The five-year instrument carries a 19 per cent coupon and forms part of Emzor’s N40 billion ($29.6 million) bond issuance programme.
The offer, which represents the pharmaceutical company’s second domestic bond, was oversubscribed following what the company described as strong investor demand.
Emzor said the proceeds would be used to strengthen working capital, increase manufacturing capacity and accelerate the completion of its API facility.
The fundraising comes as Nigerian pharmaceutical manufacturers face persistent challenges arising from dependence on imported raw materials, foreign exchange shortages, exchange-rate volatility and disruptions in global supply chains.
The completion of Emzor’s anti-malarial API plant is therefore expected to have implications beyond the company’s own expansion plans.
APIs are the active substances in medicines responsible for producing their therapeutic effects. Most pharmaceutical ingredients used by African drug manufacturers are sourced from outside the continent, leaving local producers vulnerable to fluctuations in international supply and prices.
By producing key pharmaceutical ingredients locally, manufacturers could reduce their exposure to some of these external pressures while improving the availability and security of essential medicines.
Emzor’s investment is particularly significant given Nigeria’s heavy reliance on imported pharmaceutical ingredients and finished products.
Increased domestic API production could reduce import dependence, ease some cost pressures associated with foreign sourcing and contribute to the development of a stronger local pharmaceutical value chain.
Founded in 1977 by pharmacist Stella Okoli as a small chemist shop in Lagos, Emzor has grown into one of Nigeria’s leading pharmaceutical manufacturers.
The company currently manufactures more than 120 medicines across 16 therapeutic categories.
The latest bond issuance represents a further stage in its evolution, with the company seeking to move beyond the production of finished medicines into the manufacture of critical inputs required by the pharmaceutical industry.
The planned API facility is designed to support the domestic production of anti-malarial pharmaceutical ingredients, potentially reducing the need for local manufacturers to source such inputs from overseas.
Malaria remains a major public health challenge in Nigeria and across Africa, making the availability of reliable supplies of anti-malarial medicines and their key ingredients strategically important.
The investment also aligns with broader efforts to increase local content in Nigeria’s healthcare and pharmaceutical sectors.
For domestic manufacturers, greater control over the supply of APIs could provide a buffer against disruptions in international logistics, currency instability and sudden changes in the cost of imported raw materials.
The N26.7 billion financing will consequently provide Emzor with additional capacity to pursue its manufacturing expansion while advancing the development of the API plant.
The oversubscription of the bond also points to investor confidence in the company’s expansion strategy and the potential of Nigeria’s pharmaceutical manufacturing sector.
As the company deploys the funds, the success of the project could strengthen local pharmaceutical production, create additional opportunities for value addition and contribute to efforts to build a more resilient medicine supply chain in Nigeria and the wider West African market.
Leave a Reply